Treating Erectile Dysfunction in Diabetes Patients

Diabetes Educator

Volumn 23, Issue 1, 1997, Pages

  Saulie, Barbara A ^a   Campbell, R Keith ^a,b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASODILATOR AGENT;

DIABETES MELLITUS; HUMAN; IMPOTENCE; INJECTION; MALE; METHODOLOGY; PATIENT EDUCATION; PENIS PROSTHESIS; REVIEW; SUCTION;

DIABETES COMPLICATIONS; HUMANS; IMPOTENCE; INJECTIONS; MALE; PATIENT EDUCATION; PENILE PROSTHESIS; SUCTION; VASODILATOR AGENTS;

EID: 0030639364     PISSN: 01457217     EISSN: None     Source Type: Journal    
DOI: 10.1177/014572179702300103     Document Type: Review

References (40)

1. Krane RJ, Goldstein I. Impotence period. N Engl J Med 1989;321:1648-59.
2. Hakim LS, Goldstein I. Diabetic sexual dysfunction. Endocrinol Metab Clin North Am 1996; 25(2):379-400.
3. National Institutes of Health. Impotence. National Institutes of Health consensus statement. Bethesda, Md: National Institutes of Health, 1992;10:1.
4. Feldman H, Goldstein I, Hatzichristou DG, Krane R, McKinlay J. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol 1994;151:54-61.
5. 1 for the treatment of erectile impotence. J Urol 1989;141: 323-25.
6. 1. J Urol 1989;141:1357-59.
7. Heyden B, Donatucci C, Kaula N, Lue T. Intacavernous pharmacotherapy for impotence: selection of appropriate agent and dose. J Urol 1993; 149:1288-99.
8. 1 in the treatment of erectile dysfunction. J Urol 1988;140:525-27.
9. Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet 1985;1:181-84.
10. Lerner S, Melman A, Christ G. A review of erectile dysfunction: new insights and more questions. J Urol 1993;149:1246-55.
11. Kirby R. Impotence: diagnosis and management of male erectile dysfunction. Br Med J 1994; 308:957-61.
12. Tejada IS. Pathophysiology of erectile dysfunction. In: Erectile dysfunction: intracavernosal pharmacotherapy [Symposium]. Universal City, Calif: Mar, 1996.
13. Kim N, Vardi Y, Padma-Nathan H, Daley J, Goldstein I, Saenz de Tejada. Oxygen tension regulates the nitric oxide pathway. J Clin Invest 1993; 91:437-41.
14. 1 in erectile failure: a survey of worldwide experience. J Urol 1996;155:802-15.
15. Kwan M, Greenleaf WJ, Mann J, Crapo L, Davidson JM. The nature of androgen action on male sexuality: a combined laboratory self-report study. J Clin Endocrinol Metab 1983;57:557-62.
16. Franks S, Jacobs HS, Martin N, Nabarro JD. Hyperprolactinemia and impotence. Clin Endocrinol 1978;8:277-87.
17. Krane RJ, Goldstein I, Saenz de Tejada I. Medical progress: impotence. N Eng J Med 1989; 321:1648-49.
18. Hengeveld MW. Erectile disorders: a psychosexological review. In: Jonas U, Thon WF, Steif CG, eds. Erectile dysfunction. New York: Springer-Verlag, 1991:207-21.
19. Steele D. Drugs causing sexual dysfunction and their alternatives: a reference tool. Urol Nurs 1989;Oct-Dec.
20. Nadig PW. Vacuum therapy and other devices. In: Bennett AH, ed. Impotence. Philadelphia: WB Saunders, 1994:251-56.
21. Nadig PW, Ware JC, Blumoff R. Noninvasive device to produce and maintain an erection-like state. J Urol 1986;27:126-31.
22. Montague DK, Lakin MM. Penile prostheses. In: Bennett AH, ed. Impotence. Philadelphia: WB Saunders, 1994:257-95.
23. Barada JH, McKimmy RM. Vasoactive pharmacotherapy. In: Bennett AH. Impotence. Philadelphia: WB Saunders, 1994:229-50.
24. 1 as treatment for erectile dysfunction. J Urol 1995;153: 80-81.
25. 1. J Urol 1991;146:786-89.
26. 1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses. J Urol 1996;155:913-14.
27. Shenfeld O, Hanani J, Shalhav A, Vardi Y, Goldwasser B. Papaverine phentolamine alone for intracorporeal injection therapy: a clinical double-blind study. J Urol 1995;154:1017-19.
28. 1 and papaverine in treatment of erectile failure: double-blind crossover study among Egyptian patients. J Urol 1992;147:623-26.
29. 1 therapy for impotence, comparison with papaverine. J Urol 1990;143:57-59.
30. Goldstein I. Corporal fibrosis: incidence and management. In: Erectile dysfunction: intracavernosal pharmacotherapy [Symposium]. Universal City, Calif: Mar, 1996.
31. 1. JAMA 1991;265(24): 3321-23.
32. 1 alone. J Urol 1991;145:56-59.
33. Staerman F, Nouri M, Coeurdacier P, Cipolla B, Guille F, Lobel B. Treatment of the intraoperative penile erection with intracavernous phenylephrine. J Urol 1995;153:1478-81.
34. Lee M, Cannon B, Sharifi R. Chart for preparation of dilutions of a adrenergic agonists for intracavernous use in treatment of priapism. J Urol 1995;153:1182-83.
35. Dittrich A, Albrecht K, Bar-Moshe O, Vandendris M. Treatment of pharmacological priapism with phenylephrine. J Urol 1991;146:323-24.
36. Barada JH, Bennett AH. Therapeutic penile detumescence by corporal irrigation. Contemp Urol 1991:40-48.
37. 1 in erectile dysfunction. Br J Clin Pharmacol 1989;28:567-71.
38. Lewis RW, King BF. The diagnostic algorithm. In: Bennett AH, ed. Impotence. Philadelphia: WB Saunders, 1994:42-51.
39. Vinik A, Richardson D. Diabetic erectile dysfunction. In: Erectile dysfunction: intracavernosal pharmacotherapy [Symposium]. University City, Calif: Mar, 1996.
40. Gomaa A, Shalaby M, Osman M, et al. Topical treatment of erectile dysfunction: randomized double-blind placebo control trial of cream of aminophylline, isosorbide dinitrate, and codergocrine mesylate. Br Med J 1996;312:1512-15.